Sriram Venkataraman, Avista Partner said, "Inform Diagnostics' precision and laboratory excellence have earned the trust of clinicians and enhanced patient care. During Avista's ownership period, Inform Diagnostics executed on a host of compelling corporate and growth initiatives, including the appointments of numerous senior team members, enhanced financial flexibility to drive corporate growth and strengthened compliance policies and procedures. Shortly thereafter, Inform Diagnostics grew its capabilities via the acquisition of Therapath, a leading neuropathology laboratory based in New York and the expansion of its Newton, Massachusetts facility. In 2017, Avista's Fund IV carved out Inform Diagnostics from Miraca Life Sciences and worked diligently with the newly recruited management team to create a successful standalone company. The company currently provides services to approximately 1,300 clients who represent over 2,700 physicians.įulgent Genetics originally announced its definitive agreement to acquire Inform Diagnostics for approximately $170 million on April 18, 2022. Inform Diagnostics is one of the largest national pathology laboratories in the United States with offerings across gastrointestinal pathology, dermatopathology, urologic pathology, and hematopathology, among others. NEW YORK, Ap/PRNewswire/ - Avista Capital Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announced that it has closed on the sale of Inform Diagnostics ("Inform Diagnostics") to Fulgent Genetics (NASDAQ: FLGT).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |